Introduction {#s1}
============

The most remarkable achievement in the battle against the Human Immunodeficiency Virus (HIV) is the discovery of very efficient, well-tolerated combinational antiretroviral therapy (ART) that has transformed the deadly viral infection into a chronic, manageable disease. In the absence of a cure, HIV-infection requires lifelong treatment. Though treatment successfully controls HIV-replication, and prevents opportunistic infections, HIV-infected persons on long term ART suffer from some maladies that are typically associated with human aging ([@B1]). The effect of HIV-associated inflammation and immune activation on the premature onset of immunosenescence despite effective viral suppression are thought to be the primary reasons for early aging in people living with HIV (PLHIV) ([@B2]).

Chronic, low-grade systemic inflammation resulting from an increased pro-inflammatory state contributes to the progressive pathophysiological changes associated with aging. This process of increase in pro-inflammation followed by a chronic inflammatory state is termed as "inflamm-aging" and is a significant risk factor for morbidity and mortality in the elderly people ([@B3]). The inflammatory environment triggers the development of several age-related non-infectious comorbidities (NICMs) ([@B1]). In HIV infection, it is believed that viral persistence in a rare population of long-lived, latently infected cells despite successful ART contributes to the chronic inflammatory state ([@B1]).

Unlike in high-income countries (HIC), the ART program in low- and middle-income countries (LMIC) like India, follows a public health approach with a standardized regimen for all PLHIV. As of December 2016, nearly 1 million PLHIV were receiving free ART through the government program in the country ([@B4]). The recommended first-line ART regimen includes one non-nucleoside reverse transcriptase inhibitor (NNRTI), either nevirapine (NVP) or efavirenz (EFV), in the backbone of two nucleoside reverse transcriptase inhibitors (NRTI), either zidovudine (AZT), or tenofovir (TDF), and lamivudine (3TC) ([@B5]). Although perfect adherence to treatment remains a challenge, the reasonably good response to first-line therapy indicates the overall success of the ART program in the country ([@B6]). Thus, with the expansion of the ART program and its consequences in PLHIV, the burden of age-related non-AIDS diseases are likely to increase. Since the environment has an enormous impact on age and age-related diseases, and the genetic determinants of aging may vary across populations, studies conducted in HICs might not apply to the LMICs ([@B7]).

The present study attempted to evaluate HIV-associated inflammation and immune activation and the contribution to inflamm-aging in PLHIV on long-term combination ART (cART) by assessing markers of inflammation as well as aging, including a panel of 92 inflammatory markers, two well-characterized immune activation markers (sCD14 and sCD163), and telomere length. The study provides useful insights into the role of inflammation and aging in HIV-1 infected individuals despite successful ART.

Materials and Methods {#s2}
=====================

Study Design and Participants
-----------------------------

The study included three groups of individuals: (i) treatment-naïve PLHIV with viremia and moderate CD4 count (Pre-ART herein) (ii) PLHIV of age between 35 and 60 years on ART for more than 5 years with suppressed viremia on national first-line ART and \>90% adherence to treatment (ART herein), and (iii) life-style, age, and gender-matched (with ART group) HIV-1 negative healthy individuals free of any kind of chronic illness (HIVNC herein). The HIV-1 positive cohort was recruited from a tertiary care ART Center at the Government Hospital for Thoracic Medicine (GHTM), Chennai, India, at the time of routine standard-of-care hospital visit. Exclusion criteria were pregnancy in women, Immune Reconstitution Inflammatory Syndrome (IRIS), presence of co-infections like active tuberculosis or hepatitis virus infection, history of co-morbidities like diabetes mellitus, obesity, evidence of cardiovascular disease or any chronic illness, illicit drug usage, alcohol consumption, and intake of anti-inflammatory drugs in the past 1 month. For the ART group, we screened 258 individuals and recruited 55 persons who matched the above criteria for the study. After screening 166 individuals for the pre-ART group, 41 who met the eligibility criteria were recruited for the study. Plasma viral load was measured using the *Abbott* RealTime HIV-1 viral load assay (Abbott, US). Two individuals in the ART group had viral load \>150 copies/mL (4,000 and 1,800 copies/mL, respectively) and had to be excluded from the study. We screened 295 healthy individuals in and around Chennai, India, and identified 43 lifestyle, age, and gender-matched individuals for the HIVNC group.

The overall study design is presented in [Figure 1](#F1){ref-type="fig"}. After first-time counseling and obtaining informed consent to participate in the study, 15 mL of venous blood was collected from each study participant.

![Flow diagram of study design and experimental plan. 424 HIV-1 positive individuals and 295 HIV-1 negative healthy controls were screened. Following defined inclusion and exclusion criteria, 43 healthy controls, and 53 HIV positive ART-experienced subjects and 41 ART-naïve HIV-1 positive subjects were recruited for the study. The methodology used for the study is also presented.](fimmu-10-01965-g0001){#F1}

Proteomic Profiling of the Soluble Factors in Plasma
----------------------------------------------------

Plasma samples from the Pre-ART, ART, and HIVNC groups were subjected to soluble proteome analysis using the Olink® Inflammation Panel that includes 92 inflammation-related soluble factors (Olink Bioscience AB, Uppsala, Sweden) ([@B8]). Of the 92 proteins, only 75 were detectable in \>50% of the samples, and therefore our analysis was restricted to these proteins alone. Two Pre-ART samples and one HIVNC sample did not pass the quality control and had to be excluded from our analysis. We also measured two widely reported biomarkers of immune activation, sCD14 (Human CD14 Quantikine ELISA Kit R&D Systems, UK) and sCD163 (Thermo Scientific™ Pierce™ Human CD163 Kit, Thermo Scientific, USA) in plasma.

Telomere Length in Peripheral Blood Mononuclear Cells (PBMC)
------------------------------------------------------------

As a molecular biomarker of "biological aging," the leucocyte telomere length was measured in PLHIV on ART and HIV-negative controls. Genomic DNA was extracted from PBMC using the QIAamp *DNA Mini Kit* (*Qiagen, Germany*) and telomere length was measured using the Absolute Human Telomere Length Quantification qPCRAssay Kit (AHTLQ; ScienCell Research Laboratories, US) following manufacturer\'s instructions. All samples were tested in triplicate.

Total HIV-1 DNA Quantification Using IC-qPCR Marker for HIV-1 Reservoir Level
-----------------------------------------------------------------------------

To quantify total HIV-1 DNA from PBMC, internally controlled qPCR (IC-qPCR) was performed as described previously ([@B9]). IC-qPCR was performed in duplicate using 500 ng template DNA and Takara Premix Ex Taq™ (Probe qPCR) (Takara, Japan). Primers targeting HIV-1 LTR and Beta-globulin were used. Total HIV-1 DNA copy numbers were calculated based on the linear equation of the 10-fold Beta-globulin standard curve derived from Jurkat cells and the 10-fold pNL4-3 plasmid standard curve, diluted in 50 ng/μL of Jurkat DNA to mimic clinical samples and normalized to obtain HIV-1 DNA copies per million PBMC.

Statistical Analysis and Data Visualization
-------------------------------------------

Based on the normality of the data Mann Whitney *U*-test, Spearman correlation and one-way analysis of variance (ANOVA) were performed to investigate the difference in mean levels of protein expression (NPx) in the different groups under study. Multivariate linear regression for the outcome of telomere length was used to investigate the association between HIV status and HIV treatment duration adjusting for chronological age as well as other disease and patient characteristics. These same models were used to investigate evidence of mediation of the HIV-telomere relationship by soluble biomarkers. Feature ranking process using Random Forest algorithm was executed using R package randomForest. A heatmap was generated to visualize the clustering of samples based on protein expression using *gplots* v3.0.1 in R. Similarity in protein expression within the groups was visualized using a principal component analysis using PCAtools. All other analysis was performed using base R. *P*-values are not corrected for multiple comparisons, although false discovery rate was used in some of the biomarker discovery analyses.

Ethical Clearances {#s3}
==================

The study was approved by the Institutional Ethics Committee of the National Institute for Research in Tuberculosis (NIRT IEC No: 2015023) and Institutional Review Board of the Government Hospital for Thoracic Medicine (GHTM-27102015) Chennai, India. All the study participants gave written informed consent. Patient identities were anonymized and delinked before analysis.

Results {#s4}
=======

Patient Characteristics
-----------------------

Cohort characteristics are presented in [Table 1](#T1){ref-type="table"}. All three cohorts were gender-matched. There were 51, 43, and 51% of females in the Pre-ART, ART, and HIVNC, respectively. The median age of ART, Pre-ART, and HIVNC groups were 45, 40, and 46 years, respectively. In the ART group, the median (IQR) duration of treatment was 8 years (6--10 years). As per the inclusion criteria, all the patients had \>90% of self-reported adherence which was further confirmed by viral load \<150 copies/mL and very low-level HIV-1 reservoir with median (25th−75th) 2.87 (2.62--3.18) log~10~ copies/10^6^ PBMC. Within the ART group, 57% (30/53) were on zidovudine, lamivudine, and nevirapine (ZDV/3TC/NVP) regimen and the remaining 43% (23/53) were on tenofovir, lamivudine, and efavirenz (TDF/3TC/EFV) regimen. All individuals were initiated on antiretroviral treatment in the chronic phase of the disease with a median (25--75th) CD4 count of 186 (100--280) cells/μL, as per the National guidelines for eligibility to ART existing then.

###### 

Patients\' demographic and clinical parameters.

  **Parameter**                                                                    **Treatment naïve (Pre-ART)**   **Treatment experienced (ART)**   **HIV-negative control (HIVNC)**   ***P*-values**
  -------------------------------------------------------------------------------- ------------------------------- --------------------------------- ---------------------------------- -------------------------------------------
  *N*                                                                              41                              53                                43                                 ND
  Gender, Female, *N* (%)                                                          21 (51)                         23 (43)                           22 (51)                            0.6734[^\#^](#TN2){ref-type="table-fn"}
  **At sampling**                                                                                                                                                                       
  Age in years, median (IQR)                                                       40 (37--43)                     45 (42--49)                       46 (40--54)                        \<0.0001[^\*^](#TN1){ref-type="table-fn"}
  CD4 count (cells/μL); median (IQR)                                               367 (251--578)                  667 (476--797)                    NA                                 \<0.0001[^§^](#TN3){ref-type="table-fn"}
  CD8 count (cells/μL); median (IQR)                                               1,138 (872--1,625)              772 (337--1,092)                  NA                                 \<0.0001[^§^](#TN3){ref-type="table-fn"}
  CD4:CD8 ratio, median (IQR)                                                      0.329 (0.1,863--0.529)          0.76 (0.575--1.013)               NA                                 \<0.0001[^§^](#TN3){ref-type="table-fn"}
  Viral Load, Log~10~ copies/mL, mean (SD)                                         4.4943 (0.9036)                 2.14                              NA                                 \<0.0001[^§^](#TN3){ref-type="table-fn"}
  Years on treatment, median (IQR)                                                 NA                              8 (6--10)                         NA                                 ND
  Treatment Regimen, *n* (%)                                                                                                                                                            
  ZDV+3TC+NVP                                                                      NA                              30 (57%)                          NA                                 ND
  TDF+3TC+EFV                                                                                                      23 (43%)                                                             
  CD4 Count at treatment initiation (cells/μL), median (IQR)                       NA                              186 (100--280)                    NA                                 ND
  HIV-1 Reservoir by total DNA count, log~10~ copies/mL/10^6^ PBMC, Median (IQR)   ND                              2.87 (2.62--3.18)                 ND                                 ND

*NA, Not available; ND, Not Done*;

*Kruskal-Wallis test*,

*χ^2^ test*,

*Mann-Whitney test*.

*ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; TDF, tenofovir and EFV, efavirenz; PBMC, Peripheral blood mononuclear cells*.

Soluble Markers of Immune Activation in Plasma
----------------------------------------------

Soluble markers of immune activation, sCD14, and sCD163, were measured in plasma samples of the three study groups. PLHIV had significantly higher levels of sCD14 ([Figure 2A](#F2){ref-type="fig"}) and sCD163 ([Figure 2B](#F2){ref-type="fig"}) in plasma as compared to HIVNC (*p* \< 0.001, Mann Whitney *U*-Test). Interestingly, despite prolonged suppressive ART (median duration of 8 years of cART), there was no significant decline in the levels of sCD14 in PLHIV. Levels of sCD163 were significantly lower in the ART group as compared to the Pre-ART group (30,014 pg/mL vs. 68,192 pg/mL, *p* \< 0.001, Mann Whitney U Test), but were significantly higher as compared to the HIVNC group (*p* = 0.04, Mann Whitney *U*-Test). We did not find any significant correlation between duration of cART and sCD14 (Spearman r: 0.163; *p* = 0.2432) or sCD163 (Spearman r: 0.154; *p* = 0.2720) levels in the ART group.

![Plasma immune activation markers. Soluble CD14 **(A)** and CD163 **(B)** in plasma of the three groups of individuals were measured using ELISA.](fimmu-10-01965-g0002){#F2}

Soluble Markers of Inflammation in Plasma
-----------------------------------------

To identify candidate biomarkers for future study, we looked for biomarkers that differed significantly between the groups by Random Forest (RF) analysis ([Figure 3A](#F3){ref-type="fig"}). The proteins with the most significant differences were TNFRSF9, sCD6, sCD5, TRANCE, and CXCL9. The supervised principal component analysis (PCA) based on the top 30 proteins that were identified as in RF showed that 82% (32/39) of Pre-ART samples grouped together ([Figure 3B](#F3){ref-type="fig"}). In HIVNC, 74% (31/43) grouped together while in the ART group, 94% (50/53). Three ART patients grouped together closely with the Pre-ART group. Hierarchical clustering analysis (HCA) with top 20 proteins, revealed a large cluster of 25 Pre-ART samples (cluster 1) along with several small clusters of ART and HIVNC samples together (cluster 2a). Five protein clusters were also identified with a group-specific distinct profile ([Figure 3C](#F3){ref-type="fig"}).

![Plasma inflammation markers. **(A)** The random forest (RF) analysis of soluble factors resulted in predictive accuracies of 86.6% for HIVNC, Pre-ART, and ART. The soluble factors importance plots display the top 30 metabolites, which most strongly contribute to the groups\' separation for HIVNC, Pre-ART, and ART. **(B)** Principal component analysis using PCAtool indicating grouping in different disease categories. **(C)** Hierarchical clustering analysis of ANOVA of top 20 differentially expressed proteins with false discovery rate (FDR) \<0.001.](fimmu-10-01965-g0003){#F3}

Among the 75 proteins, 40 showed a significant difference (*p* \< 0.05, Tukey HSD) between at least one of the groups compared (ART vs. Pre-ART, Pre-ART vs. HIVNC and ART vs. HIVNC; [Figure 4A](#F4){ref-type="fig"}). Levels of 30 inflammatory proteins were found to be significantly different between the Pre-ART and HIVNC groups, 38 proteins were significantly different between the Pre-ART and ART groups, and 11 proteins were significantly different (*p* \< 0.01, Tukey HSD) between the HIVNC and ART groups ([Figure 4B](#F4){ref-type="fig"}). Out of 11 proteins, 4E-BP1 was found to differ significantly only between the ART and HIVNC groups, and not between any of the other groups. Five proteins were different between all the three groups (CD8A, TRANCE, sCD5, SLAMF1, and CCL23; [Figure 4B](#F4){ref-type="fig"}). Of the proteins that showed a significant difference between the ART and HIVNC groups, levels of soluble NT3, CD5, TRAIL, and TRANCE were lower, but levels of ADA, MMP1, CST5, and 4E-BP1 were higher when compared to both HIVNC and Pre-ART groups. On the other hand, CD8A, SLAMF1, and CCL23 were higher in the ART group as compared to the HIVNC group ([Figure 4C](#F4){ref-type="fig"}). CD8A, SLAMF1, and CCL23 also strongly correlated with each other and with other interleukins (IL18, IL10, and IL6) in the ART group ([Figure 4D](#F4){ref-type="fig"}). Interestingly in the ART group, 20 proteins were correlated with sCD163, but only three proteins CCL23, CCL3, and IL6 along with sCD163 correlated with sCD14 ([Supplementary Figure 1](#SM2){ref-type="supplementary-material"}).

![Comparative analysis of the proteins that differed significantly between groups. **(A)** Proteins that have statistically significant difference (*p* \< 0.05, Tukey HSD) (in dark blue shade) between at least one of the groups compared (ART vs. Pre-ART, Pre-ART vs. HIVNC and ART vs. HIVNC). **(B)** Venn diagram showing significantly different protein in the study group. The sum of the numbers in each large circle represents the total number of differentially expressed proteins in plasma in the different groups (HIVNC vs. ART, Pre-ART vs.ART, and Pre-ART vs. HIVNC). The overlapping part of the circles represents significantly different proteins in the indicated groups. **(C)** Comparative analysis of 11 soluble markers that are significantly different between ART and HIVNC. **(D)** Heatmap and clustering of significantly different proteins on their protein-protein pair relation by Spearman-correlation in ART patients. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.001.](fimmu-10-01965-g0004){#F4}

Telomere Length
---------------

Telomere length was analyzed only in two groups (HIVNC and ART) as PBMC were not available for the Pre-ART group. Linear regression analysis, after adjusting for chronological age, and gender showed a significant negative association of HIV-1 positive status on telomere length (−2.84, 95%CI, −4.012, −1.67, *p* \< 0.0001) with the ART group having significantly shorter telomeres. However, no significant association was observed between duration of treatment and telomere length after adjusting for age and markers of disease progression within the ART group. Several of the biomarkers considered were significantly associated with telomere length after adjustment for age, HIV status, and gender; these include CXCL1 and CD40 which are both weakly positively associated with telomere length, MMP-10, and CX3CL1, which are positively associated with telomere length. OSM (Oncostatin M) is negatively associated with telomere length. The results are outlined in detail in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}. Within the ART group, after adjusting for age, gender, duration of treatment, CD4 count at initiation, CD8/CD4 ratio, and sCD14, we observed CXCL1 and TGF-α to have a significant association with increased telomere length (0.2905, 95%CI: 0.0029,0.5780 *p* = 0.048) and (0.7865, 95%CI: 0.1003, 1.4727, *p* = 0.026), respectively. We also found that IL-10RA was significantly associated with decreased telomere length (−1.79, 95%CI: −3.51, −0.07 *p* = 0.042).

Discussion {#s5}
==========

This study examined a cohort of PLHIV on long-term successful cART from India and found that despite a median duration of 8 years of suppressive cART, several soluble inflammatory markers that were found to be elevated in HIV-1 infected untreated subjects, were also significantly elevated in the ART group as compared to the HIVNC group. This study found higher levels of the inflammatory protein CST5, as compared to HIVNC, in addition to higher levels of 4E-BP1, SLAMF1, CCL23, and lower levels of NT3 proteins, for the first time in PLHIV on long term cART. This is the first study from India in a standardized public health setting with standard first-line cART which observed that despite successful long-term cART, persistent immune activation, and residual inflammation exist in PLHIV who are therefore at higher risk of inflamm-aging and age-related diseases as these biomarkers were previously shown to be associated with several age-related diseases (summarized in [Table 2](#T2){ref-type="table"}).

###### 

Summary of statistically different proteins between ART and HIVNC and their role in disease pathogenesis and biomarkers of age-associated diseases.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Protein**                                   **Function**                                                                                                                                                    **Described in age-related diseases**                                                           **References**
  --------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------
  4E-BP1 (Q13541)                               Mediator of the regulation of protein translation through the MAP kinase and mTORC1 pathways.                                                                   Hepatocellular carcinoma (HCC), cancer                                                          ([@B10])

  Adenosine Deaminase (ADA) (P00813)            Plays an important role in purine metabolism and enhances CD4^+^ T-cell differentiation and proliferation.\                                                     Cardiovascular diseases, stroke, acute lymphoblastic leukemia                                   ([@B11], [@B12])
                                                Enhance HIV-1 effector responses by restoring T lymphocyte function                                                                                                                                                                                             

  CCL23 (P55773)                                Shows chemotactic activity for monocytes, resting T-lymphocytes, and neutrophils                                                                                Rheumatoid arthritis, atopic dermatitis, atherosclerosis                                        ([@B13])

  CD5 (P06127)                                  May act as a receptor in regulating T-cell proliferation.                                                                                                       Rheumatoid arthritis                                                                            ([@B14])

  CD8A (P01732)                                 Plays an essential role in the immune response against both external and internal stimuli\                                                                      Gastric cancer, asthama                                                                         ([@B15], [@B16])
                                                Marker of CD8 T-cell activation in HIV-infection.                                                                                                                                                                                                               

  Cystatin D (CST5) (P28325)                    May play a role in controlling proteolytic activity during inflammatory processes                                                                               Traumatic brain injury                                                                          ([@B17])

  Matrix metalloproteinase-1 (MMP-1) (P03956)   Cleavage of several types of collagens, interacts and cleaves the secreted HIV-1 Tat protein, leading to a decrease in neuronal Tat\'s mediated neurotoxicity   Arthritis, ulcerative colitis, coronary atherosclerosis, cancer                                 ([@B18]--[@B22])

  Neurotrophin-3 (NT-3) (P20783)                Promoting the survival and differentiation of neurons as well as neurogenesis                                                                                   Neuro-cognitive impairment, multiple sclerosis, coronary atherosclerosis                        ([@B23]--[@B25])

  SLAMF1 (Q13291)                               Role in controlling innate and adaptive immune responses                                                                                                        Rheumatoid arthritis                                                                            ([@B26])

  TRAIL (P50591)                                An immune effector protein which induces apoptotic cell death of cancerous or infected cells.\                                                                  Rheumatoid arthritis, atherosclerosis, psoriasis, Alzheimer disease.                            ([@B27])
                                                Involve in HIV-1 pathogenesis by inducing CD4^+^ T-cell death                                                                                                                                                                                                   

  TRANCE (RANKL) (O14788)                       Plays important roles in dendritic cell maturation and survival, regulation of T cell-dependent immune response, and stimulation of osteoclastogenesis          Rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, non-traumatic fracture   ([@B28], [@B29])
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*The uniport id is given along with the protein name*.

It has been reported that certain age-related NICMs like diabetes mellitus, cardiovascular disease, cancer, bone fracture, and renal failure, are more common among HIV-1 infected individuals as compared to the general population. Exposure to prolonged cART along with low-grade inflammation and persistent immune activation seen in HIV-infection is thought to be the cause for the increased risk of NICMs ([@B2], [@B30]). Chronic inflammatory conditions and persistent immune activation are believed to be the major drivers of aging physiology. Inflammatory biomarkers of aging and their association with co-morbid diseases have been studied well in many elderly populations. Proteins like 4E-BP1 and the association of mTOR with aging and age-related diseases ([@B31], [@B32]), has already been documented. However, there are no studies that have examined the response of plasma 4E-BP1 to ART. We found higher levels of 4E-BP1 in the ART group as compared to both HIVNC and the Pre-ART group, suggesting that this marker may be associated with duration of HIV infection and/or exposure to anti-retroviral drugs and could serve as potential biomarkers of immune-aging related to HIV and long-term ART.

In the case of well-studied immune activation markers, the ART group had significantly higher levels of sCD14 like that seen in the Pre-ART group. Contradictory results have been reported from different studies on the effect of cART on sCD14 ([@B33]--[@B35]) due to a variety of contributors ([@B36], [@B37]). On the other hand, sCD163, a marker of vascular inflammation ([@B38]) and neurocognitive impairment ([@B39]), was higher in PLHIV than in healthy controls, which is in contrast to previous reports ([@B40]) but in line with other studies which showed that sCD163 was higher compared to the HIV-negative controls within 2 years of therapy ([@B41], [@B42]). The novelty of our study was to explore a large panel of inflammatory markers and we showed significantly higher levels of MMP1 ([@B43]), ADA ([@B44]), CD8A ([@B16]), SLAMF1 ([@B45]), and CCL23 ([@B46]) in PLHIV on long term ART. Many of these markers have been reported to be linked with early stages of various age-related diseases, including atherosclerosis, arthritis, cardiovascular diseases ([Table 2](#T2){ref-type="table"}).

sCD5 and TRAIL have been reported as biomarkers of inflammation and related diseases in both HIV-infected as well as uninfected individuals ([@B47]--[@B49]). We found lower levels of sCD5 and TRAIL in the ART group as compared to the HIVNC group. Lower plasma and cerebrospinal fluid levels of TRAIL were observed in early Alzheimer Disease (AD) ([@B50]). The TRAIL-mediated apoptosis also plays an essential role in the clearance of virus-infected cells. An earlier study proposed to use TRAIL agonist in patients with prolonged viral suppression to eradicate the latent HIV-1 reservoir in CD4^+^ T cells and macrophages ([@B51]). The lower level of TRAIL in patients with long term ART could hinder the clearance of the latent HIV-1 reservoir and dampen immune responses to other viral infections including influenza and cytomegalovirus ([@B27]). CD5, a negative regulator of antigen receptor signal transduction in lymphocytes ([@B52]), is reported to stimulate the production of the anti-inflammatory cytokine IL-10 by B-cells ([@B53]). Low levels of sCD5 in HIV-infected individuals, associated with the existing pro-inflammatory state, could promote the development of age-related cancers and other diseases in these individuals. An earlier study conducted in a Swedish cohort reported normalization of sCD5 to a healthy state upon anti-HIV treatment ([@B54]), which is in contrast to our findings. However, the Swedish cohort was on two-decades-long successful therapy and was initiated on ART in the early stages of HIV-infection, unlike our cohort which was started on ART only in stage 2 or 3 of the disease as per national guidelines and policies available then.

TRANCE/RANKL, an essential regulator of bone metabolism, was found to be lower in the ART group than in HIVNC. There is existing literature to show that HIV-infected individuals treated with NRTIs and NNRTIs have lower than normal levels of circulating RANKL ([@B55]). Lower levels of TRANCE have been reported as an independent predictor of non-traumatic fracture, indicating its effect on osteoclastogenesis ([@B29]). Though Cystatin D (CST5) has not been well-studied in HIV, our study showed altered levels of this protein in HIV-1 infected individuals. CST5 is ultra-early inflammatory marker of traumatic brain injury ([@B56]). To the best of our knowledge, this is the first study reporting elevated levels of CST5 in HIV infection.

NT3, another inflammatory marker, is reported to be strongly associated with neurocognitive impairment in PLHIV ([@B24], [@B25]) and MMP1 with senescence-associated conditions ([@B57], [@B58]). Higher levels of these two proteins could be favoring age-associated changes and premature aging in HIV-infected individuals with prolonged exposure to cART. The decreased expression of NT3 was also observed in colorectal cancer ([@B59]), while increased levels of plasma MMP1 have been associated with coronary atherosclerosis ([@B20]) and cancers ([@B21], [@B22]) providing further evidence to support the role of these proteins in disease development during aging.

Higher levels of CCL23 and SLAMF1, which are involved in monocyte activation, in the ART group could contribute to the sustained release of sCD14 ([@B60]). Further, continued immune activation could be due to several other mechanisms including, sustained HIV-replication in reservoir sites like lymph nodes and gastrointestinal tract ([@B61]), low levels of HIV and its proteins ([@B62], [@B63]), altered gut microbiota in PLHIV ([@B64]), and different ART regimens ([@B65]).

Telomere length (TL) is a marker of replicative senescence and is a well-known predictor of health outcome in aging populations. Chronic inflammation can potentially contribute to age-related diseases through increased production of reactive oxygen species that damage telomeres and lead to cellular and immunological senescence ([@B66]). Several studies have noticed an association between TL and age-related diseases ([@B67]). In HIV infection, immune activation, and expanded proliferation of leukocyte subsets immediately after infection, along with uncontrolled viremia have been associated with a rapid decrease in TL ([@B68]), followed by increase in TL with ART initiation. However, telomere induced replicative senescence with long term ART has also been reported ([@B69]). Our study also found shorter telomeres in PLHIV on ART for \>5 years and noticed a significant association between TL and inflammatory markers like CXCL1, TGF-α, and IL10RA. Telomere length shortening has been well-reported in several inflammatory conditions and related diseases like cancer. Zadka et al. ([@B70]) showed a positive correlation between IL10RA expression and disease pathogenesis in colorectal cancer ([@B70]).

Our study has some limitations that merit comment. First, the HIV-infected population selected for this study were from the best pool of successfully treated individuals (free of co-infections and co-morbidities), through the Indian National ART program. The findings may not generalize to the general population of treated HIV-1 positive individuals. Second, due to the lack of earlier studies in this setting, the design of our study, and limited sample size, the conclusions drawn are limited to associations with modest significance. Also, many statistical tests were run, but only the most significant results have been highlighted, for this reason, the results should be considered hypothesis generating. Third, the patients were not monitored virologically as a standard of care, and we only have virological data at the time of sampling. Any potential viral blips which are most unlikely reflected by the patients CD4 history could have introduced bias in the expression of inflammatory markers. However, among the few studies involving inflammatory markers in virally suppressed populations from LMICs ([@B71], [@B72]), our study is the first comprehensive study on markers associated with inflammation and aging, that compared a large panel of inflammatory markers in PLHIV on long term suppressive ART from India, which uses a standardized public health approach for HIV-treatment monitoring. Finally, the telomere length comparison between the ART group and the HIVNC could not be adjusted for health factors or disease progression markers, such as CD4 as these were not measured on HIVNC. As Telomere length was taken as the average for PBMCs, the difference in CD4 and CD8 cells percentages may have contributed to the magnitude of the difference; further studies investigating difference based on cell type are needed.

In conclusion, we observed several soluble inflammatory biomarkers that differed significantly between PLHIV and healthy individuals, despite 8 years of successful therapy- Interestingly, several of these biomarkers have been previously shown to be associated with inflammatory conditions like cancer, cardiovascular, neurological and skeletal diseases.

Put together, these data suggest that HIV-1 infected individuals, even those on long-term successful ART, may be at higher risk of developing inflammatory diseases leading to inflamm-aging. The low-grade chronic inflammation is a major risk factor for the development of many age-associated diseases and to some extent morbidity and mortality in elderly people even in the general population. Therefore clinical and nutritional intervention or use of anti-inflammatory drugs may potentially be considered in this population that can reduce the burden of excessive immune activation and inflammation. Besides, we found a significant difference in telomere length between subjects on long-term ART and HIVNC subjects, even after adjusting for age; this warrants further investigation.
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